Abstract: Diabetic retinopathy (DR) is a severe complication of diabetes that affects the retinal structures and can lead to significant visual impairment or even blindness. Early diagnosis is crucial ...

Valo Health’s Rho kinase (ROCK) 1 and 2 inhibitor has failed to reduce the severity of diabetic retinopathy in a phase 2 trial, leading the Flagship-founded biotech to drop the candidate.